ESMO 2025 | What to look forward to in GU cancers at ESMO 2025
Toni Choueiri, MD, Dana-Farber Cancer Institute, Boston, MA, discusses highlights from ESMO 2025 including the advancement of radioligand therapy in prostate cancer and major developments in bladder cancer, with positive trials in non-muscle invasive disease, frontline combinations, and ctDNA-based approaches that could change practice. In kidney cancer, attention is on the adjuvant RAMPART trial (NCT03288532) exploring dual CTLA-4 and PD-L1 inhibition, with preliminary but promising data, particularly in non-clear cell cohorts. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
